Blue Horseshoe Stocks: LPCN Recap, LPDX & More

Lipocine, Inc. LPCN

LPCN served up an opportunity at some decent intraday gains after appearing on yesterday morning’s extended watchlist.

The stock played out a classic dip and rip scenario, falling to a morning low of 6.89 before surging back in the afternoon to a subsequent high of 8.42. That offered traders a chance at intraday gains of up to 22% on plenty of liquidity- the stock would trade 23.5X its 30-day average volume.

The productive session came on the heels of the company announcing favorable results from Phase-3 clinical testing of “LPCN 1021”, its oral treatment for low testosterone >>> VIEW PR


LipoScience, Inc. LPDX

LPDX is gapping up heavily in the premarket, and the interesting story behind it is one that we’re definitely going to want to give our close attention. Early this morning, the company announced that it was the subject of a buyout that would be executed at a share price of $5.25. Barely an hour later, another PR hit the LPDX newswire, concerning an investigation of the managerial board’s handling of the deal, and whether or not they have secured the best possible buyout price.

According to the investigative firm leading the case, “The $5.25 per share acquisition price is far less than where the stock has recently traded. In fact, on January 25, 2013, LipoScience stock opened for trading at $9.75 the day the Company sold 5.0 million shares of stock in its initial public stock offering.” >>> VIEW PR

The playing out of this scenario is going to be an interesting story moving forward, which is why we wanted to flag LPDX this morning, and fill everyone in on this morning’s happenings. The possibility that the investigation could lead to a potential restructuring of the buyout is enough to have us keep our ears to the tracks on this one for the foreseeable future.


Magnum Hunter Resources Corp. MHR

MHR is another morning gapper that we’re putting on our radars. This morning Magnum announced impressive throughput volumes on its “Eureka Hunter” gas gathering pipeline. According to the CEO, “increased capacity has resulted in a record day of approximately 316,500 MMBtu of natural gas”. >>> VIEW PR


Options Trading Idea: PBR Calls 

We’re interested in the PBR October 31st $15.50 Calls  last traded at 1.88. If we can see PBR make its way back to recent $20+ highs within a month, it could put us in position to see returns of up to 150-200% on those contracts.


Extended Watchlist:
 RNN, MNKD, CNET, VHC, MPET

Blue Horseshoe Stocks: MACK, RITT, BIGG & More


Merrimack Pharmaceuticals, Inc. MACK

We’ve got MACK, a play that has been on our watchlist before, bringing itself to the forefront today as news about a licensing agreement has the stock gapping up to the tune of 20% in the premarket. We’re going to be interested to see how it comes out of the gate this morning in response to the announcement.

Baxter International Inc. (BAX) and Merrimack Pharmaceuticals, Inc. (MACK) today jointly announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 >>> GO TO PR


RiT Technologies, Inc. RITT

Another gapper, RITT is also up significantly in premarket trading this morning. The stock had a strong session yesterday, trading in a range from 1.28 – 1.97 on exceedingly heavy volume; more than ten times the monthly average, so we are looking at it for potential momentum carryover into today.

Given the nature of the yesterday’s activity, we could also be looking at a possible dip-and-rip scenario as inevitable profit-taking pares back the share price.


Big Tree Group, Inc. BIGG

BIGG was actually passed along to us awhile back by one of our subscribers. (Readers should feel encouraged to share any ideas you might have with us!) Since then we’ve had the stock on the back burner, passively following along until it was ripe for the picking. We began to see some positive movement off of the bottom yesterday, so we think now could be a good time to flag this play for more intensive monitoring.


Added Note – Options Trading Idea

GTLS was the subject of a buyout rumor yesterday, which effected some upwad movement in the stock. As a result we just want to radar the October $65 Calls, which last traded at 1.50.


Extended Watchlist:
LPCN, ICLD, BBRY, BBBY, SINO

Blue Horseshoe Stocks: CNET Recap & More

ChinaNet Online Holdings, Inc. CNET

CNET made an excellent move following its inclusion in yesterday’s morning report, as the stock would go on to trade in an impressive range from  a low of 2.41 up to a new annual high of 3.98 on nearly 34x its one-month average volume. The strong 65% intraday run came in the first hour of trading, so folks had the chance at some very rapid, very substantial gains. Congrats if you were among them!


Direxion Daily Jr Gld Mnrs Bear 3X ETF (JDST)

We introduced JDST as a way to leverage against the falling prices of gold yesterday, and it’s working out in our favor so far. This ETF didn’t waste any time Monday morning, as it began a morning ascent that would last all day and carry it from a low of 14.65 to 16.88, a modest yet solid gain of 15%

We’ll have our eyes on this one for as long as it appears that the dollar will continue to strengthen.


OTHER ITEMS OF INTEREST

Our scanner yielded three interesting plays with news out of varying subjects.

NXT-ID, Inc. NXTD, has a mobile wallet product that they bill as the truly the first universal secure payment solution, which, as it does not require a smart-phone, provides certain advantages over other eWallet-type products now being pushed by Apple (ApplePay) among others. The stock made a significant move in yesterday’s trading, and will be on our radars today. >>> Shareholder Update PR

China Jo-Jo Drugstores, Inc. CJJDreleased financials yesterday and received a warm reception from traders. Some of the highlights included:

  • Online sales contributed $2.6 million in revenue, an increase of 103.5% from the comparable quarter of prior year
  • Retail sales, which includes online sales, accounted for approximately 80.0% of total revenue, and increased by $2.3 million, or 20.7% year over year to $13.2 million
  • Wholesale, which accounted for approximately 20.0% of total revenue, decreased to $3.3 million from $4.4 million for the same quarter of last year. >>> VIEW FULL PR

Synthetic Biologics, Inc. SYN Earlier last wee the FDA granted orphan drug status to SYN’s monoclonal antibody (mAb) combination, “SYN-005”. After a period of consolidation off of the initial run that produced, the stock is gapping up in the premarket today, so we’ll definitely want to keep an eye peeled.


Extended Watchlist:
OTIV, NETE, NVAX, USAT